FIELD: pharmacology.
SUBSTANCE: digitoxin application is described.
EFFECT: digitoxin effectively reduces TGF-β-induced differentiation of myofibroblasts and can be used to treat idiopathic pulmonary fibrosis with a reduction in the number of complications.
2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIFIBROLYTIC MEANS | 2016 |
|
RU2621163C1 |
| HDAC INHIBITORS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS AND OTHER INFLAMMATORY PULMONARY DISORDERS | 2021 |
|
RU2833349C1 |
| AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2013 |
|
RU2530651C1 |
| METHOD FOR MANUFACTURING PHARMACEUTICAL COMPOSITION IN FORM OF EXTENDED-RELEASE TABLETS CONTAINING PIRFENIDONE AND USE THEREOF IN REGRESSION OF CHRONIC RENAL INSUFFICIENCY, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS IN HUMANS | 2012 |
|
RU2682177C2 |
| ORVEPITANT FOR CHRONIC COUGH TREATMENT | 2016 |
|
RU2746601C2 |
| AGENT FOR PULMONARY FIBROSIS CONTAINING PYRAZOLE DERIVATIVE | 2021 |
|
RU2817989C1 |
| DRUG FOR TREATMENT OF TISSUE FIBROSIS BASED ON COMPONENTS OF SECRETOME OF MESENCHYMAL STROMAL CELLS, METHOD FOR OBTAINING AND APPLYING REMEDY | 2020 |
|
RU2766707C1 |
| ANTAGONISTS OF ENDOTELINE RECEPTOR INTENDED FOR EARLY STAGE OF IDIOPATIC PULMONARY FIBROSIS | 2007 |
|
RU2435585C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| MEDICATION, CONTAINING FGF2 AS ACTIVE INGREDIENT, FOR TREATMENT OR PREVENTION OF ASTHMA AND CHRONIC OBSTRUCTIVE LUNG DISEASES | 2005 |
|
RU2351356C2 |
